Voices
Amisha Gupta: Feasibility, Toxicity, and Modest Efficacy of Accelerated Glofitamab Step-Up Dosing in High-Risk R/R DLBCL
Amisha Gupta/X

Amisha Gupta: Feasibility, Toxicity, and Modest Efficacy of Accelerated Glofitamab Step-Up Dosing in High-Risk R/R DLBCL

Amisha Gupta, Chief Heme/Onc fellow at Moffitt Cancer Center, shared Blood Journals Portfolio’s post on X, adding:

“Grateful to share our Blood ICT study: in high-risk R/R DLBCL, accelerated glofitamab step-up dosing was feasible (81% to target dose <21 days) but with toxicity and modest efficacy, underscoring the need for better strategies.

Thank you Michael Jain and Julio Chavez.”

Quoting Blood Journals Portfolio’s post:

“Accelerated single-agent glofitamab SUD was feasible in high-risk R/R DLBCL; 81% reached target dose in <21 days.”

Amisha Gupta: Feasibility, Toxicity, and Modest Efficacy of Accelerated Glofitamab Step-Up Dosing in High-Risk R/R DLBCL

Title: Accelerated step-up dosing of glofitamab in rapidly progressive R/R DLBCL: a real-world cohort analysis

Authors: Fnu Amisha, Syeda Saba Kareem, Hanna Bailey, Kiranpreet Kaur, Biwei Cao, Ning Dong, Samuel Reynolds, Nima Ghalehsari, Abu-Sayeef Mirza, Omar Castaneda Puglianini, Aleksandr Lazaryan, Celeste Bello, Leidy Isenalumhe, Yumeng Zhang, Sameh Gaballa, Lubomir Sokol, Frederick Locke, Bijal Shah, Javier Pinilla-Ibarz, Julio Chavez, Michael Jain

Read the Full Article on Blood Immunology & Cellular Therapy 

Amisha Gupta: Feasibility, Toxicity, and Modest Efficacy of Accelerated Glofitamab Step-Up Dosing in High-Risk R/R DLBCL

Other posts featuring Amisha Gupta on OncoDaily.

Abu-Sayeef Mirza Aleksandr Lazaryan Amisha Gupta Bijal Shah Biwei Cao Blood Journals Portfolio cancer Celeste Bello DLBCL Fnu Amisha Frederick Locke Hanna Bailey Javier Pinilla-Ibarz Julio Chavez Kiranpreet Kaur Leidy Isenalumhe Lubomir Sokol Michael Jain Nima Ghalehsari Ning Dong Omar Castaneda Puglianini OncoDaily Oncology Sameh Gaballa Samuel Reynolds Syeda Saba Kareem Yumeng Zhang